Diagnos’ Andre Larente on the benefits of using AI for the early detection of critical health issues

“Our (AI) technology works, its in production (CARA). We are fully funded….the markets we are going after are extremely big…” are excerpts that Andre Larente of Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF) offered Tracy Weslosky of InvestorIntel in a recent interview.

Tracy starts the interview by identifying the increasing interest from the global market on the Canadian biotech sector. She asks Andre to identify their competitive advantages for investors seeking to understand this market better. Andre explains “we specialize in using AI to tackle some of the medical imaging issues in the world.”

Click here to hear the full interview and learn more about how Diagnos offers early detection medical tests for a wide spectrum of critical medical issues that range from diabetes to cardiovascular issues.

About Diagnos:

Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF) is a publicly traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet and is compatible with all

recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.

Disclaimer: *Diagnos Inc. is an advertorial member of InvestorIntel Corp.*

Non-invasive diabetes test provides “Miraculins” results through technology

June 12, 2015 – Tracy Weslosky, Editor-in-Chief and Publisher of InvestorIntel speaks to Christopher Moreau, President, CEO & Director for **Miraculins Inc.** (TSXV: MOM) about the Scout technology, a non-invasive diabetes test and their recent *promising results* as supported by the joint MIraculins and Amway Scout DS® study being accepted for the 23rd World Congress of Dermatology. In addition to this, a follow-up on the recent good news from the FDA and an update on the $90mm value deal with a Chinese pharmaceutical company, they discuss Miraculins shareholder value and health issues relating to diabetes.

Tracy Weslosky: Today I have the pleasure of speaking with Chris Moreau from Miraculin. Of course, you have the non-invasive diabetes testing – you got ‘the Scout’?

Christopher Moreau: Yes, we have the Scout.

Tracy Weslosky: What I would like to know, but what's happening with the U.S. FDA?

Christopher Moreau: We had very good news that we had announced, based on our feedback from the U.S. FDA that we are going to continue down a pathway called the de novo path for a class 2 device in the U.S. and we hope to have some additional news soon for the market.

Tracy Weslosky: For those of us that may not understand the biotech industry as well as Chris does, can you tell us what this means for the timeline and why this is such exciting news?

Christopher Moreau: What it means is that typically in the U.S. to go for a class 2 designation you need to have a predicate device meaning there needs to be a comparable device on the market that you can point to. There is no predicate device for the Scout, but there's an exception in the U.S. FDA called the de novo pathway where if you don't have a predicate device you can rely on this pathway. It's much easier than being a class 3. That's much more expensive. It's more time consuming and if we can continue for a de novo pathway for the U.S. FDA in the Scout, it's very good news for shareholders.

Tracy Weslosky: This is very good news for shareholders, so can you tell us what this process timeline might be like, best-case scenario?

Christopher Moreau: Generally speaking, studies for a class 2 depends on the size of the study. There are some details we're still working through with the FDA so I'm not going to be able to give you a specific timeline. We are hoping to begin more specific plans for a study in the fall. The size of the study and how long it will take we'll be able to update the market at that time.

Tracy Weslosky: Of course, you just put out news about a study that you've done with Amway. Can you tell us more about this?

Christopher Moreau: Yes. Amway reached out to us and wanted to do a study. They have a device that's very expensive that can scan a person's skin and tell whether that skin's been damaged either by excessive UV, damage below the surface. This is a device that they use that is very expensive. It's not mobile. They had read about the Scout and….to access the rest of this interview, click here

Disclaimer: Miraculins Inc. is an advertorial member of InvestorIntel.

The big business of age-management through skin pre-testing

It was my perception in meeting Miraculins Inc. (TSXV: MOM), CEO Chris Moreau last night that he is dedicated to his company and truly wants to help people. Miraculins have a diagnostic device for painless screening of pre-diabetes that has the potential for many other uses, called the Scout DS® – I told him about the time I had a diabetes screening and was bruised halfway up my arm. Because of this, the Scout's needle free, light activated test really appeals to me.

This morning Miraculins announced they will present a peer reviewed scientific poster at the 23rd World Congress of Dermatology. The poster will present secure information from patient trials, including a study done with Amway. Aside from predicting diabetes (the fastest growing disease in

history), the Scout also has the ability to determine skin damage from the sun by assessing advanced glycation end products, (AGE's). For this reason Miraculins is teaming up with Amway Corporation's Open Innovation Team, who market skin products and supplements.

The conference is the world's oldest and continuous international dermatology meeting, and will be held in Vancouver, BC from June 8-13, 2015. The poster will be entitled, *The Association of Skin Glycation with Facial Skin Aging.* This device could be used to screen for many other possible health issues, since AGE's are also potential biomarkers for atherosclerosis, chronic renal failure, and Alzheimer's disease. The device is a kiosk, much like the blood pressure cuffs found in most pharmacies. Because the device is painless, quick and doesn't require a doctor, there is potential for high numbers of people to make use of this state of the art diagnostic tool.

Many people don't like going to the doctor, or waiting weeks for test results, the Scout changes all that. Of course people are advised to follow up with their doctors. But as people become more aware of the risks of diabetes, and UV radiation, the desire to find out so easily is likely to be greater than the desire to have your blood drawn. And some people spend more on skin care products in a year than they do on food. Being able to know how much your skin is aging, and the vitamin supplements that can help slow the aging process is a big business. And Amway sells those products for the skin, including Nutrilite™ vitamin, mineral and dietary supplements, and Artistry™ skincare and colour cosmetics, amongst many other supplements and products. World wide sales in 2014 made Amway the #1 direct selling business globally, according to Direct Selling News.

Miraculins and Amway collaborated on a study, using the Scout on 555 women between the ages of 16 and 82, including a mixed race cohort. Subjects were evaluated through a cross-sectional

survey using a questionnaire that accounted for age, ethnicity, BMI, smoking, sun protection habits, years working outdoors, vitamin supplementation, skin care habits, tanning, history of type 1 or 2 diabetes, as well as kidney, heart and skin disease. Skin AGE's were measured utilizing the Scout, and facial wrinkling and skin lightness were measured using standardized facial photography and analysis techniques.

The Scout is an easy to use kiosk that provides results in 90 seconds. This is very unlike other tests for diabetes that require needles, trips to the doctor, and weeks to get results. That the device can also be used to determine the aging of the skin is perhaps only the first of many other unmet needs that Miraculins' device could be used for. The simplicity of getting results in 90 seconds for the fastest growing disease in history is an advantage that could see the device installed not just in pharmacies, but airports and other public areas worldwide. For instance, Miraculins released news May 22nd 2015 that it has now completed all required preparations for the submission of its Scout device for product testing in compliance with Chinese Food and Drug Administration (CFDA). Maybe we will be seeing this device at many locations near you in the not too distant future.

Miraculins on the $90mm value non-invasive diabetes test deal and pioneering

diagnostic testing

January 27, 2015 – Tracy Weslosky, Editor-in-Chief and Publisher of InvestorIntel speaks to Christopher Moreau, President, CEO & Director for Miraculins Inc. (TSXV: MOM) about the Scout technology, a non-invasive diabetes test and their recent $90mm value deal with a Chinese pharmaceutical company. They also discuss the significant milestones for 2014 and looking ahead as Miraculins focuses on diagnostic tests and risk assessment technologies for unmet clinical needs.

Tracy Weslosky: Chris, I'm very excited to speak with you because, first of all, I love the stock. This is MOM, M-O-M on the TSX Venture Exchange. Of course, your most recent news release is about your accomplishments for 2014.Why don't we start there?

Christopher Moreau: Okay, let's. Our first major accomplishment for 2014 was the signing of an up to $90 million deal value with a Chinese pharmaceutical company. This is a company that reached out to Miraculins when we acquired the Scout technology. They have distribution of pharmaceutical and small medical devices in the Chinese hospital market. They contacted us when we acquired the Scout. They said they had been following the technology for some time and they wanted the rights to China. After a number of trips to the Chinese market and working out the best possible distribution deal we announced a deal in August. That deal includes a milestone upfront payments, a $15 million dollar guaranteed order when we achieve Chinese FDA clearance, which we are anticipating to happen in the next 12 to 16 months and an additional $15 to $20 million per year to maintain their exclusivity in years 2, 3, 4 and 5. It's a major deal for Miraculins. It's the first time we can actually point to a potential revenue stream that is contractually– is part of a contractual agreement.

Tracy Weslosky: For everyone out there, we have a junior with cash and you heard that correct, a $90 million dollar deal from last year. Let me back you up. Can you tell us who is Miraculins? And, tell us just a little bit about yourself.

Christopher Moreau: Miraculins is a Canadian-based medical device company. Our focus is non-invasive diagnostic tests and screening tests. We have two lead technologies. One is a technology for cholesterol, tissue cholesterol called PreVu. It's a 5 minute test. We don't need a blood drawn. You don't need to fast. Tissue cholesterol is an independent risk factor for heart disease. Our second lead technology is the Scout. This is the world's first no blood drawn, no fasting screening test for pre-diabetes and type 2. We have 38.7 million shares out in terms of our corporate structure. We just closed a financing for 1.3 million in December. That's a 50,000 foot view of Miraculins.

Tracy Weslosky: Alright, so we have the big deal in China. I just want to take you back now to the most recent new release because you mentioned all – in the news release, all your accomplishments for the highlights for 2014. I actually think that there was more in addition to that large deal.

Christopher Moreau: There were. In 2014 the financial markets were difficult so access to capital was tough. We did have to focus our initiatives. Two or three other accomplishments for us in the year, we interfaced with the U.S. FDA. The Scout is approved in Canada and it's cleared for sale in Europe. The discussions we had with the FDA in the U.S. was to try to clarify what the best regulatory pathway is for the Scout. Having met with the FDA on a number of occasions, we plan to go back to them. The FDA has an…to access the rest of the interview, click here

Disclaimer: Miraculins Inc. is an advertorial member of InvestorIntel.